Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX-CL-09e phenserine-tartrate 26-week double-blind extension in mild to moderate Alzheimer's disease
2005-000063-25Phase 3Completed
- Sponsor
- Axonyx
- Start
- Mar 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of phenserine in Alzheimer's disease (AD), sponsored by Axonyx. Primary endpoints: Long-term efficacy profile and Long-term safety profile. Started Mar 2005; status: completed.
02
Drugs
phenserine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-000063-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000063-25.